Several phase-III trials of (neo)adjuvant therapy with ICIs are underway, with expansion of this treatment approach to reduce recurrence in high-risk patient populations (i.e., patients with TN, HR-positive/HER-2-negative, and HER-2-positive breast cancers; lymph node metastasis; or locally advanced cancer with residual tumor cells after NAC). Here, ERBB2 is linked to breast carcinoma.